Formulation of temozolomide-loaded nanoparticles and their targeting potential to melanoma cells
Open Access
- 29 December 2016
- journal article
- Published by Spandidos Publications in Oncology Reports
- Vol. 37 (2) , 995-1001
Abstract
Spandidos Publications is a scientific publisher with a long-standing international reputation for excellent standards and high quality science publicationsKeywords
This publication has 24 references indexed in Scilit:
- PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanomaOncotarget, 2015
- Chemotherapy in the management of advanced cutaneous malignant melanomaClinics in Dermatology, 2013
- Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistanceNature, 2013
- Nanotechnology: Carrying drugsNature, 2012
- Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trialCancer Chemotherapy and Pharmacology, 2012
- Molecular mechanisms of temozolomide resistance in glioblastoma multiformeExpert Review of Anticancer Therapy, 2012
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- Dendrimers in gene deliveryAdvanced Drug Delivery Reviews, 2005
- Treatment of Brain Metastases of Malignant Melanoma with TemozolomideNew England Journal of Medicine, 2001
- Enhancement of Progenitor Cell Division in the Dentate Gyrus Triggered by Initial Limbic Seizures in Rat Models of EpilepsyEpilepsia, 2000